Public Funding for Epsilogen Ltd

Epsilogen (formerly IGEM Therapeutics) is developing a novel HER2-targeted antibody EPS 201, selected on a number of key attributes that sets it apart from marketed competitors. The project seeks to move EPS 201 closer to the clinic through development of product quality assays, _in vivo_ models for GLP toxicology and efficacy, and a manufacturing cell line for progression to GMP. IgE provides a completely unique anti-cancer mode of action which enables our products to be clearly differentiated from IgG-based therapies.

IGEM Therapeutics Ltd aims to develop new platform technologies for creating therapeutic IgE molecules with enhanced anti-tumour activities. The Fc region of IgE has been engineered to introduce additional functionality with a view to improving anti-tumour responses, in particular for treatment of solid tumours. An immediate output of the project will be a FRa-targeting variant IgE antibody with superior anti-cancer activity. It is expected that a cohort of ovarian cancer patients who are presently poorly served by targeted therapies will be early beneficiaries of such a modality. More generally, the project addresses the pressing need to provide better outcomes for patents with solid tumours. IGEM aims to attain a leading position in the global immune-oncology market which is forecast to reach $28 billion by 2025\.

IGEM Therapeutics Ltd aims to develop a novel HER2-targeted antibody that will address a number of unmet clinical needs. It will exploit innovative animal models, novel HER2-binding antibody domains and its innovative IgE platform technology. IgE provides a completely unique anti-cancer mode of action which enables our products to be clearly differentiated from IgG-based therapies. IGEM aims to attain a leading position in the global immune-oncology market which is forecast to reach $28 billion by 2025\.

IGEM-C is an IgE-based antibody targeting a melanoma antigen. The project involves the evaluation of a number of novel variants of the prototype for efficacy, manufacturability and stability. The antigen target for IGEM-C is found in many different solid tumours, and part of the project will be to develop animal models for these indications. The chosen variant will be evaluated for efficacy in the new animal models. A GMP manufacturing process will be developed and preclinical studies will be planned which are compliant with regulatory requirements for a Phase 1 clinical trial in patients with solid tumours bearing the target antigen for IGEM-C. The overall aims of the project are to select the preferred clinical candidate, expand the indications that it could target, and carry out all the essential steps to allow IGEM-C to progress rapidly towards a Phase 1 trial once the project is complete.